InMed Pharmaceuticals Inc.
INM · XNASCIK 1728328fmd_1A47FQ1QX1QZADESTC9WQJHZ3PManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2019 to Sep 30, 2026, 29 periods
Latest annual · FY2025
Millions- Total revenues
- 5
- Gross profit
- 2
- Operating income
- (7)
- Net income
- (13)
Latest quarter · Q1 FY2027
Millions- Net income
- (2)
Daily close · INMIEX trades only
Aug 05, 2025 to Nov 04, 2026 · 250 sessions1.81 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +65.5%
- Net income, 5 yearsFY2021 to FY2026
- n/m
InMed Pharmaceuticals Inc. (INM) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Net income | -$12.6 million | -$1.7 million | 10-K 2026-09-09 · proof | |
| Cash from operating activities | -$8.6 million | -$8.1 million | 10-K 2026-09-09 · proof | |
| Total assets | $3 million | $15.6 million | -80.6% | 10-K 2026-09-09 · proof |
| Total liabilities | $2 million | $2.1 million | -8.9% | 10-K 2026-09-09 · proof |
| Cash and cash equivalents | $2.2 million | $10.7 million | -79.6% | 10-K 2026-09-09 · proof |
- What was InMed Pharmaceuticals Inc. (INM)'s net income in fiscal 2026?
- InMed Pharmaceuticals Inc. (INM) reported net income of -$12.6 million for fiscal 2026 (the year ended Jun 30, 2026), against -$1.7 million the year before. Source: the 10-K filed with the SEC on Sep 9, 2026. SEC
- What was InMed Pharmaceuticals Inc. (INM)'s cash from operating activities in fiscal 2026?
- InMed Pharmaceuticals Inc. (INM) reported cash from operating activities of -$8.6 million for fiscal 2026 (the year ended Jun 30, 2026), against -$8.1 million the year before. Source: the 10-K filed with the SEC on Sep 9, 2026. SEC
- What are InMed Pharmaceuticals Inc. (INM)'s total assets?
- As of Jun 30, 2026, InMed Pharmaceuticals Inc. (INM) reported total assets of $3 million, against $15.6 million a year earlier (-80.6%). Source: the 10-K filed with the SEC on Sep 9, 2026. SEC
- What are InMed Pharmaceuticals Inc. (INM)'s total liabilities?
- As of Jun 30, 2026, InMed Pharmaceuticals Inc. (INM) reported total liabilities of $2 million, against $2.1 million a year earlier (-8.9%). Source: the 10-K filed with the SEC on Sep 9, 2026. SEC
- What are InMed Pharmaceuticals Inc. (INM)'s cash and cash equivalents?
- As of Jun 30, 2026, InMed Pharmaceuticals Inc. (INM) reported cash and cash equivalents of $2.2 million, against $10.7 million a year earlier (-79.6%). Source: the 10-K filed with the SEC on Sep 9, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:INM&period_type=annual&limit=5"Information only, not investment advice.